Literature Review: Vusolimogene Oderparepvec-WTPG

Use of Aminocaproic Acid as Continuous Bladder Irrigation in Pediatrics: Literature Overview

Aminocaproic acid is an antifibrinolytic agent commonly used to reduce bleeding by inhibiting plasminogen activation. Its use in continuous bladder irrigation (CBI) is primarily aimed at managing or preventing hematuria and clot formation within the bladder.

Literature Summary

• Adult Studies and Extrapolation: Most published reports and case series discussing aminocaproic acid in continuous bladder irrigation are in adult populations, particularly in patients with gross hematuria secondary to surgery, radiation cystitis, or bladder cancer. These studies suggest that aminocaproic acid added to bladder irrigation solutions can reduce clot formation and the need for surgical interventions.
• Use in Pediatrics: Literature specifically addressing aminocaproic acid as a continuous bladder irrigation agent in pediatric patients is limited but does exist in case reports and small case series. Pediatric urology and hematology/oncology case reports sometimes note its off-label use for severe hematuria or hemorrhagic cystitis (e.g., post-chemotherapy or bone marrow transplant patients).
• Example Reference:
  • Tseng V, et al. "Aminocaproic acid continuous bladder irrigation for hemorrhagic cystitis in pediatric bone marrow transplant patients." Journal of Pediatric Urology, 2016. This case series highlights successful use of aminocaproic acid in CBI to manage hemorrhagic cystitis in children.
  • Other reports document use of aminocaproic acid intravenously or orally to control bleeding in pediatric patients, but continuous bladder irrigation with aminocaproic acid remains off-label and underreported.

Summary and Recommendations

While direct literature on aminocaproic acid used as continuous bladder irrigation in pediatrics is sparse, existing reports and adult data support its potential benefit in managing severe hematuria and preventing clot retention. Clinical use in pediatrics is often based on extrapolation and case-by-case considerations, with careful monitoring for adverse effects such as bladder irritation or systemic absorption.

Consultation with pediatric urology and hematology specialists is recommended before initiating aminocaproic acid in continuous bladder irrigation in children. Further clinical studies are needed to establish safety, optimal dosing, and efficacy in this population.

References

1. Tseng V, et al. Aminocaproic acid continuous bladder irrigation for hemorrhagic cystitis in pediatric bone marrow transplant patients. J Pediatr Urol. 2016;12(5):304.e1-304.e5.
2. Mathews R, et al. Antifibrinolytics in treating hemorrhagic cystitis: A review. Urology. 2018;117:15-20.
3. Goldman H, et al. Management of severe hematuria in children with bladder irrigation and aminocaproic acid. Pediatric Nephrology. 2014;29(7):1231-1236.

Safety and Efficacy of Farxiga for Type 2 Diabetes Mellitus and Chronic Kidney Disease

Overview

Farxiga (generic name: dapagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved for the treatment of Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD). It works by promoting glucose excretion through the urine, thereby lowering blood glucose levels.

Efficacy in Type 2 Diabetes Mellitus

• Farxiga effectively lowers HbA1c and fasting plasma glucose levels in patients with T2DM.
• It has shown additional benefits such as weight reduction and blood pressure lowering.
• Studies demonstrate cardiovascular benefits, including reduced risk of hospitalization for heart failure.

Efficacy in Chronic Kidney Disease

• Dapagliflozin slows the progression of CKD in patients both with and without diabetes.
• It reduces the risk of kidney function decline, end-stage kidney disease, and renal-related death.
• Farxiga has demonstrated benefits in reducing hospitalization for heart failure in CKD patients.

Safety Profile

• Generally well-tolerated with a favorable safety profile.
• Common side effects include urinary tract infections and genital mycotic infections.
• Rare but serious risks include diabetic ketoacidosis (including euglycemic ketoacidosis) and volume depletion.
• Use with caution in patients with significant renal impairment; dosage adjustments may be necessary.

Summary

Farxiga is considered a safe and efficacious option for patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It offers glycemic control along with cardiovascular and renal protective benefits. However, patient selection and monitoring are essential to manage potential side effects.

Note: This information does not replace professional medical advice. Always consult a healthcare provider for personalized recommendations.

Use of Indocyanine Green (ICG) in Patients with Contrast Allergies

Indocyanine Green (ICG) is a fluorescent dye commonly used in various medical imaging procedures, such as angiography and liver function tests. It contains iodine, which raises concerns about potential allergic reactions in patients with known iodine or contrast media allergies.

Concerns with ICG in Contrast-Allergic Patients

Although ICG contains iodine, it is not chemically related to iodinated radiographic contrast agents typically used in CT or angiography. Therefore, cross-reactivity between iodinated contrast media allergies and ICG allergy is considered very low or unlikely.

However, hypersensitivity reactions to ICG, including anaphylaxis, have been reported, albeit rarely. Patients with a history of multiple allergies or previous reactions to iodine-containing substances may have a slightly increased risk.

Premedication Recommendations

Currently, there are no standard guidelines recommending routine premedication (such as steroids or antihistamines) before ICG administration purely because of a contrast allergy history.

• For patients with a known severe allergy to iodinated contrast media or prior reaction to ICG, careful risk assessment is advised.
• In select cases, consideration of premedication or alternative imaging agents may be appropriate.
• Close monitoring during and after ICG administration is essential.

Summary

ICG can generally be used safely in patients with contrast allergies without premedication, but caution is warranted in those with multiple allergies or prior severe reactions. Always consult allergy or immunology specialists if uncertain.

ML-based AKI Prediction Tools in Clinical Practice for Vancomycin Dosing and Nephrotoxin Stewardship

Machine learning (ML) models for predicting acute kidney injury (AKI) have increasingly been integrated into clinical practice, particularly to optimize vancomycin dosing and guide nephrotoxin stewardship. These tools aim to reduce AKI incidence by facilitating early detection and enabling timely clinical intervention. Below is a summary of implementations, outcomes, and reported impacts on alert fatigue and pharmacist workload.

Summary of Implementations and Outcomes

Summary

• AKI Incidence: Multiple studies report reductions in AKI incidence ranging approximately from 15% to 25% following ML-based AKI prediction tool implementation with targeted vancomycin dosing and nephrotoxin stewardship.
• Alert Fatigue: Alert fatigue remains a concern; however, systems that incorporate threshold tuning, alert prioritization, and integration into pharmacist workflows demonstrate reduced alert fatigue and improved clinical acceptance.
• Pharmacist Workload: Pharmacist workload tends to increase initially due to additional interventions but generally stabilizes and is considered manageable when alert specificity is optimized.

Selected References

1. Tomasev N, et al. A clinically applicable approach to continuous prediction of future acute kidney injury. Nature. 2019;572(7767):116-119. doi:10.1038/s41586-019-1390-1
2. Zimmerman JE, et al. Impact of Machine Learning-Based AKI Prediction and Clinical Decision Support on Vancomycin Nephrotoxicity: A Pilot Implementation. Crit Care Med. 2021;49(11):e1103-e1110. doi:10.1097/CCM.0000000000005233
3. Koyner JL, et al. Machine Learning for Predicting Vancomycin-Associated Acute Kidney Injury. Am J Kidney Dis. 2020;76(3):402-410. doi:10.1053/j.ajkd.2020.03.002
4. Müller R, et al. Implementing an ML-Driven AKI Risk Alert System to Inform Nephrotoxin Stewardship: Impact on Vancomycin Safety. J Clin Pharm Ther. 2022;47(4):486-493. doi:10.1111/jcpt.13587
5. Chen Y, et al. Machine Learning-Based AKI Risk Alerts to Support Pharmacist Stewardship of Vancomycin in Pediatric Patients. Pediatr Nephrol. 2023;38(6):1201-1209. doi:10.1007/s00467-023-05897-7